Because we were unable to control for these confounders in our specimens, it is unclear how they may have impacted tumor and HLA-DRB1 fucosylation and CD4+ T cell biology and thus the strength of correlations between these markers and responsiveness to treatment. The gene discussed is HLA-DRB1; the disease is neoplasm.